 (Circulation Research 1991;68:1302-1312 
10.2, 112.4, and 222.4 mg/kg/day. In untreated CM hamsters, in vitro left ventricular performance progressively deteriorated with increasing age beginning at roughly 180 days. This decline in left ventricular performance was accompanied by a decrease in coronary flow and an increase in left ventricular volume. Administration of quinapril from 180 to 300 days of age prevented the decline of in vitro left ventricular contractile performance and coronary flow and also reduced the age-dependent increases in left ventricular volume. The cardioprotective effects of quinapril were observed at doses of 112.4 and 222.4 mg/kg/day but not at 10.2 mg/kg/day. Lung angiotensin converting enzyme activity was significantly inhibited by quinapril in GS and CM hamsters at 240 and 300 days of age at all dose levels. In contrast, significant inhibition of ventricular angiotensin converting enzyme activity was observed consistently at doses of 112.4 and 222.4 mg/kg/day quinapril but not at 10.2 mg/kg/day. In the survival protocol, CM and GS hamsters were treated with vehicle or quinapril (100 mg/kg/day) from 180 to 522 days of age. During the initial 210 days of treatment (from 180 to 390 days of age) 78 .3% of the vehicle-treated CM hamsters died compared with 27.7% of quinapril-treated CM hamsters. Quinapril increased the median survival time of CM hamsters by 32.9%o (112 days) . It is concluded that chronic quinapril therapy exerts a significant cardioprotective effect and also increases survival. (Circulation Research 1991; 68:1302 -1312 T herapy for patients with congestive heart failure is changing, and in many cases the use of vasodilators has begun to replace positive inotropic agents.' Angiotensin converting enzyme (ACE) inhibitors have been shown to improve the hemodynamic status23 and exercise tolerance4,5 of patients with congestive heart failure. More importantly, their capacity to prolong life in patients with congestive heart failure was also recently demonstrated. 6 Preclinically, hemodynamic improvement78 and prolonged survival9,10 have been demonstrated fibrotic connective tissue." Although this animal model has been used to determine the effect of various pharmacological agents, including digitalis,12 calcium channel blockers,'2"13 and a,-adrenergic antagonists,14 on the progression of left ventricular failure, the effects of long-term therapy with ACE inhibitors have not been studied.
Quinapril, a new ACE inhibitor, is currently undergoing clinical development for the treatment of congestive heart failure.1516 To evaluate the potential beneficial effects of quinapril therapy in a cardiomyopathic model of congestive heart failure, the CM hamster was chronically treated with quinapril. Hemodynamic, morphological, and biochemical measurements were made during the period in which in vitro performance would normally deteriorate to assess the cardioprotective effects of such therapy. In addition, the effects of chronic quinapril therapy on survival time were assessed in a subsequent 11-month mortality study. The results of the present study provide the first report that an ACE inhibitor exerts significant cardioprotection and prolonged survival in an idiopathic model of congestive heart failure.
Materials and Methods Animals and Experimental Design
CHF 146 CM hamsters and normal Golden Syrian (GS) hamsters (Canadian Hybrid Farms, Nova Scotia, Canada) were obtained 2-3 weeks before the start of the study to equilibrate to their diet and their surroundings. They were housed in individual cages with free access to laboratory chow (Purina, Richmond, Ind.) and were maintained on a 12-hour light/dark cycle. GS and CM hamsters were agematched and randomly assigned to experimental groups. The study included three experimental protocols, which were carried out in succession. The purpose of the first protocol was to identify the time period at which in vitro left ventricular hemodynamic performance deteriorates in the CM hamster. The goal of the second study was to ascertain the ability of the ACE inhibitor quinapril to prevent the agedependent changes in left ventricular performance. In the final protocol, the effects of quinapril on survival time were assessed.
For the quinapril cardioprotection protocol, we wanted to intervene with therapy in the CM hamster after the necrotic stage (with measurable impairment of left ventricular performance) but before clinical signs of congestive heart failure were present. Based on previous reports"1"13 and the results of the initial protocol, an evaluation period beginning at 180 and ending at 300 days of age was chosen as the appropriate test interval. For this protocol, GS and CM hamsters were divided equally into two groups: in one group, the isolated heart preparation was used for the assessment of in vitro hemodynamic performance; in the other group, various biochemical markers were measured. The hamsters were studied at 180 days (before treatment began) and at 240 and 300 days of age (after 60 and 120 days of treatment, respectively). CM and GS hamsters were treated with one of three dose levels of quinapril or vehicle (10% honey water to offset the bitter taste of quinapril) administered in their drinking water. The doses of quinapril chosen were 0.1, 1.0, and 2.0 mg/ml. These doses were based on previous studies with captopril7'9 and a preliminary study (authors' unpublished observations) indicating that these doses produce circulating levels of quinaprilat (the active form of quinapril) that span the range of therapeutic levels seen in patients. Vehicle and quinapril solutions were prepared daily and provided to the hamsters in 10-ml aliquots at 8:00 AM (beginning of the light cycle). The 10-ml aliquot was chosen based on a previous study in CM hamsters in which each animal drank 5-7 ml water/day.13 Consumption was monitored to calculate average daily doses. Administration of 0.1, 1.0, and 2.0 mg quinapril/ml resulted in average daily doses of 10.2, 112.4, and 222.4 mg/kg/day, respectively.
For the mortality protocol, 180-day-old CM and GS hamsters were randomly assigned to vehicle (10% honey water) or quinapril treatment groups. Based on the results from the cardioprotection protocol, 100 mg quinapril/kg/day was chosen as the appropriate dose. On a weekly basis, the hamsters were weighed, and the volume of treatment was adjusted to the average weight of the treatment group. At the time of weighing, each hamster was inspected for signs of "wet tail," a fatal diarrhea in rodents that occurs frequently in hamsters.17 Hamsters dying with wet tail and concomitant weight loss were excluded from the study. Based on this criteria, 11 of 71 GS hamsters and 12 of 93 CM hamsters were excluded during the course of the study. In addition, three hamsters that died accidentally were excluded. The final number of hamsters in each treatment group was as follows: 43 in the CM-vehicle group, 37 in the CM-quinapril group, 31 in the GS-vehicle group, and 28 in the GS-quinapril group. The end point of the study was the death of >75% of the hamsters in the CM-quinapril treatment group.
Isolated Perfused Heart Studies
Hamsters were weighed, heparinized (1,000 units i.p.), and anesthetized with pentobarbital (50 mg/kg i.p.). Their hearts were excised and perfused by the Langendorff method at a pressure of 60 mm Hg. Aortic perfusion pressure was measured via a fluidfilled catheter (PE-100) connected to a pressure transducer (Statham P23Db, Spectramed, Oxnard, Calif.) positioned at the level of the isolated hearts. Perfusion pressure was regulated with a computer-controlled servomechanism previously described. ' Immunoreactive plasma atrial natriuretic peptide (ANP) concentration was measured using a radioimmunoassay procedure, as previously described by Brands and Freeman.20 Briefly, after administration of anesthesia (50 mg/kg i.p. pentobarbital) and removal of the heart, blood was collected from the chest cavity in tubes containing EDTA (1 mg/ml blood) and centrifuged (3,000 rpm for 15 minutes). The plasma obtained was then frozen in liquid nitrogen and stored at -70°C. Immunoreactive ANP was extracted by applying 0.75-1.0 ml plasma to disposable C18 reversed-phase Bond Elut columns (3 ml/200 mg, Analytichem International, Inc., Harbor City, Calif.) previously equilibrated with 0.1 M acetic acid. After washing with 0.1 M acetic acid, ANP was eluted with 1 ml of 50% (vol/vol) acetonitrile in 50 mM NaH2PO4, pH 7.4. The eluate containing ANP was evaporated to dryness and resuspended in 0.1 ml assay buffer immediately before assay. The extracted ANP was quantitated using a sequential-saturation, double-antibody radioimmunoassay (Peninsula Laboratories, Belmont, Calif.).
Tissue ACE activity was measured in solubilized tissue extracts from lung and ventricular muscle, using standard procedures.21,22 After administration of anesthesia (50 mg/kg i.p. pentobarbital), 0.5-g samples of the lung and the left ventricle were removed, rinsed in saline, and quick-frozen in liquid nitrogen. The tissue samples were stored at -70°C until assayed for ACE activity (within 2 months). After thawing, the tissues were blotted dry, weighed, and added to 50-ml centrifuge tubes containing 2.0 ml (heart) or 5.0 ml (lung) of "homogenization buffer," which consisted of 20 mM Tris base, 5 mM Mg (CH3COO)2, 30 mM KCI, 250 mM sucrose, and 0.5% Triton X-100, pH 8.3. The samples were then homogenized using a polytron (Brinkmann Instruments, Inc., Westbury, N.Y.) (three 5-second passes at a setting of 8). After homogenization, the polytron probe was rinsed with an additional 2.0 or 5.0 ml of homogenization buffer. All homogenization procedures were performed at 4°C. The homogenate was stored overnight at 4°C and then centrifuged at 20,000g for Figure 2B ). In contrast, LVEDP increased significantly for CM hearts as aortic perfusion pressure was increased ( Figure 2E) (Table 2) , which was collected 4-6 hours after the hamsters had been provided with their respective treatment. Lung ACE activity was not significantly different between GS and CM vehicletreated hamsters at 180, 240, or 300 days of age. Despite a lack of statistical significance, at 300 days, lung ACE activity was 38% greater in vehicle-treated CM hamsters compared with age-matched GS hamsters (Table 2) . Quinapril, at all dose levels, significantly inhibited lung ACE activity in 240-and 300-day-old GS and CM hamsters. At the lower dose level of 10.2 mg/kg/day, lung ACE was inhibited by >85%, independent of hamster strain or age group. Ventricular ACE activity was generally greater (34.6-114.6%) in vehicle-treated CM hamsters compared with vehicle-treated GS hamsters for all age Days of Age FIGURE 7. Graph showing effects of chronic quinapril administration (100 mg/kg/day) on the probability of survival of CHF 146 cardiomyopathic hamsters. M50 indicates the age for the median probability of survival. ***Significant differences in the median probability of survival, p<O.001.
groups. However, statistical significance was not achieved in all age groups. In 240-day-old hamsters, quinapril treatment significantly inhibited ventricular ACE activity at all dose levels. In 300-day-old hamsters, the ventricular ACE activity of CM hamsters was significantly inhibited at quinapril doses of 112.4 and 222.4 mg/kg/day, but not at 10.2 mg/kg/day.
Effects of Quinapril on Plasma ANP Levels Plasma ANP concentrations were significantly greater in CM hamsters compared with GS hamsters for 180-, 240-, and 300-day-old hamsters ( Table 3) . The elevated levels of plasma ANP for CM hamsters did not change significantly over the 120-day test period. Quinapril treatment had variable effects on ANP concentrations in CM hamsters. At 240 days of age, quinapril did not significantly affect plasma ANP concentrations in CM hamsters compared with vehicle-treated CM hamsters. At 300 days of age, plasma ANP concentrations of CM hamsters treated with 112.4 mg/kg/day quinapril were significantly less than those of vehicle-treated CM hamsters. In contrast, ANP levels in CM hamsters treated with 222.4 mg/kg/day quinapril were not significantly different from levels in the vehicle-treated CM hamsters.
Effects of Quinapril on Survival
The survival study ran for 342 days, beginning at approximately 180 days of age and ending at approximately 522 days of age. Figure 7 shows the effects of quinapril treatment on survival in CM hamsters. From 212 to 391 days of age, the mortality rate for quinapril-treated CM hamsters was significantly less (p<0.0001) than that for vehicle-treated CM hamsters. The probability of survival at 391 days of age was 27.7% for vehicle-treated CM hamsters compared with 78.3% for quinapril-treated CM hamsters. After 391 days of age, the mortality rate for quinapril-treated CM hamsters paralleled that of vehicle-treated CM hamsters. The median probability of survival was 340 days of age for vehicle-treated CM hamsters compared with 452 days of age for quinapril-treated CM hamsters. This represents an average increase in survival time of 112 quinapril-treated CM hamsters were alive compared with one of 43 vehicle-treated CM hamsters. Only two vehicle-treated GS hamsters and three quinapril-treated GS hamsters died over the 342-day test period (data not shown). The probability of survival was not statistically significant between the two treatment groups.
Discussion
The disease process in the CM hamster has been separated into four temporal phases: prenecrotic, necrotic or myolytic, hypertrophic, and terminal." The necrotic stage begins at 30-35 days of age and continues for 3-4 months.26 This is followed by a hypertrophic and healing stage and the beginnings of ventricular dilation. In the final stages, from 240 to 360 days of age, ventricular dilation continues, and clinical signs of congestive heart failure appear, including peripheral and pulmonary edema and decreases in physical activity." Since changes in the time course of these stages has been noted after generations of inbreeding," an initial series of experiments were performed to document the temporal progression of left ventricular failure in the CM hamster. In a subsequent series of experiments, the ability of quinapril therapy to prevent these changes was evaluated.
Left ventricular performance was assessed by determining the ability of the isolated hearts to respond to increases in workload. Workload was increased by increasing aortic perfusion pressure from 60 to 120 mm Hg in 20-mm Hg steps. Previous studies in CM hamsters have shown that increasing coronary perfusion pressure increases ventricular wall thickness through an "erectile" or hydraulic effect27-29 and that the increases in left ventricular performance result from mechanical stretch of the myofibrils at end diastole.28 In our test model, mechanical stretch due to increases in coronary perfusion pressure could result from both the erectile effect and from increases in LVEDP.
At 180 days of age, left ventricular responses to increases in aortic perfusion pressure were qualitatively similar between GS and CM hamsters, with near linear increases in LV +dP/dtmax. Although the hearts from 180-day-old CM hamsters responded in a manner similar to normal GS hearts, the absolute level of LV +dP/dtmax obtained at each incremental increase in perfusion pressure was significantly less. This was probably due to the extensive number of necrotic lesions in CM hearts present at this age.1" At 240 and 300 days of age, the left ventricular responses to increases in aortic perfusion pressure were no longer comparable between GS and CM hamsters. The responses in LV +dP/dtmax and LVEDP were unchanged for GS hamsters between 180 and 300 days, whereas for CM hamsters, responses in LV +dP/dtm,, were significantly depressed and nearly flat, and LVEDP increased progressively throughout the entire aortic perfusion pressure range. The results of these experiments are consistent with a previous study30 that indicates that the left ventricle of the CM hamster heart has a diminished ability to respond to increases in aortic perfusion pressure.
Coronary flow values were not significantly different between 180-day-old GS and CM hamster hearts. However, coronary flow values were significantly less for older (240-and 300 -day-old) CM hearts. This age-dependent decrease in coronary perfusion coincided with the age-dependent deterioration in left ventricular performance and is consistent with previous findings.31 It is not clear from these data if the deterioration in left ventricular performance and the decreases in coronary perfusion are dependent events or if they occur independently in response to the heart failure process. Perivascular fibrosis and calcified lesion, anticipated at this stage of the cardiomyopathy, would be expected to decrease coronary perfusion as well as impair ventricular stiffness and function.32,33 In addition, high levels of LVEDP may have contributed to the decrease in coronary perfusion due to compression of subendocardial capillaries.
In the second part of the investigation, the effects of quinapril on the progression of left ventricle failure were evaluated. Based on the results of the initial protocol, quinapril therapy was started at 180 days of age in three groups of CM hamsters at average daily doses of 10.2, 112.4, and 222.4 mg/kg. A fourth group of CM hamsters was treated with vehicle; these hamsters served as controls. Consistent with the initial protocol, left ventricular performance progressively deteriorated in the hearts of vehicletreated CM hamsters between 180 and 300 days of age. Quinapril therapy at the low dose level of 10.2 mg/kg/day did not significantly affect this progression. However, at the higher dose levels of 112.4 and 222.4 mg/kg/day, quinapril significantly prevented the age-dependent decline in LV + dP/dtma and significantly prevented the age-dependent increase in LVEDP. These results indicate that quinapril treatment preserves the ability of the left ventricle to respond to the effect of increasing coronary perfusion pressure and suggest a preserved ability of the heart to respond to myofibril stretch.
Consistent with the initial protocol, coronary flow was significantly less in CM hearts compared with GS hearts from 240-and 300-day-old hamsters treated with vehicle. Quinapril treatment at the daily dose levels of 112.4 and 222.4 mg/kg significantly increased coronary flow in CM hearts. The dosedependent effects of quinapril on coronary flow correlated with the beneficial effects of left ventricular performance and lower levels of LVEDP. However, quinapril also significantly increased the coronary flow of GS hearts, suggesting a direct effect on coronary flow independent of left ventricular performance. In a previous study10 with the ACE inhibitor captopril, both sham and heart-failure animals had increases in coronary flow. Therefore, it is possible that quinapril preserved coronary flow in CM hearts by preserving left ventricular performance and also by exerting a direct action on the coronary vasculature. It is tempting to speculate that quinapril may have affected the process of reparative fibrosis and thereby improved ventricular function and coronary perfusion. Although we have no direct evidence for this at this time, Michel et a134 recently demonstrated that ACE inhibition could prevent increases in the volume density of collagen in infarcted rats.
Ventricular dilation is characteristic of the CM hamster beginning in the third stage and continuing through the fourth and terminal stage of the disease.1' In this study, ventricular dilation was evident in vehicle-treated 240-and 300-day-old CM hamster hearts from a greater ventricular wall and chamber volume, without a significant difference in ventricular mass, compared with age-matched GS hamster hearts. Another indication of the beneficial effects of chronic quinapril treatment in the CM hamster was the ability of quinapril to prevent increases in ventricular wall and chamber volume. With quinapril treatment at the daily doses of 112.4 and 222.4 mg/kg/day, CM ventricular wall and chamber volume was no longer significantly different from GS ventricular wall and chamber volume. As with left ventricular performance, quinapril's effects on ventricular wall and chamber volume were dose dependent, with significant protection occurring at 112.4 and 222.4 mg/kg/day but not at 10.2 mg/kg/day.
The renin-angiotensin system is activated above normal levels in patients with congestive heart failure. 35 In the present study, tissue ACE activity levels were greater in CM versus GS hamsters, suggesting that in this animal model of idiopathic congestive heart failure the renin-angiotensin system is also activated above normal levels. In general, quinapril inhibited lung and ventricular ACE in a dose-dependent manner. For lung tissue, 85-90% of the ACE activity was inhibited at the dose level of 10.2 mg/kg/ day. Inhibition of ventricular ACE was much more variable at the low dose of quinapril (10.2 mg/kg/ day), ranging from 72% in 240-day-old CM to only 16% in 300-day-old CM hamsters. In contrast, the dose of 112.4 mg/kg/day quinapril produced a consistent inhibition of ventricular ACE ranging from 75% to 84%. The dose level of 112.4 mg/kg/day was also the level at which quinapril prevented the progression of left ventricular failure and left ventricular dilation. Collectively, these results suggest a better correlation between inhibition of ventricular ACE and cardioprotection than between lung ACE and cardioprotection. However, an effect of quinapril on ACE activity in more specific tissue compartments (e.g., vascular smooth muscle, cardiac interstitial, or cardiovascular nervous tissue) may provide a better correlation between ACE inhibition and cardioprotection. Clearly, additional studies will be necessary before any conclusions can be made on the specific tissues involved in quinapril's cardioprotective action.
Consistent with previous findings,36 plasma ANP concentration was severalfold greater in CM hamsters compared with normal GS hamsters. This was true for all age groups, and in general, the ANP concentration in CM hamsters was approximately the same independent of age. These results indicate that plasma ANP concentration was stable, albeit elevated, in the CM hamster during a time when left ventricular performance was progressively deteriorating with age. This apparent dissociation between plasma ANP concentration and severity of left ventricular failure has previously been demonstrated in the CM hamster.36 It appears that plasma ANP increases in the CM hamster during the compensatory (hypertrophic) phase and remains elevated during the development of heart failure and then decreases slightly at the end stage of the disease just before death.37 Quinapril therapy did not reverse the preexisting (180 days of age) high levels of plasma ANP in the CM hamster. This would suggest that the amount of left ventricular impairment in 180-day-old CM hamsters was sufficient to result in elevated ANP concentrations in the plasma. Although quinapril prevented any further decline in ventricular performance beyond 180 days of age, it did not reverse the preexisting decrement in left ventricular performance, which may explain its lack of consistent effect on elevated plasma ANP concentrations in CM hamsters. In addition to preventing the progression of left ventricular failure, quinapril increased the median probability of survival of CM hamsters by 32.9%. Quinapril's major effect on survival occurred during the first 210 days of treatment, after which the mortality rates were comparable between treatment groups. The beneficial effect on survival occurred at a time when quinapril prevented the progression of left ventricular failure. Although a cause and effect relation cannot be established from these data alone, the temporal association between improved ventricular performance and a decreased death rate suggests that quinapril prolonged survival by preventing the progression of left ventricular failure.
In summary, in vitro left ventricular performance progressively deteriorated in untreated CM hamsters with increasing age beginning at 180 days of age. This progressive decline in left ventricular performance was accompanied by decreases in coronary flow and increases in left ventricular volume. Administration of quinapril from 180 to 300 days of age prevented the decline of in vitro left ventricular contractile performance and coronary flow and also reduced the increases in left ventricular volume. In addition, chronic quinapril therapy prolonged median survival by 32 .9%. It is concluded that chronic quinapril therapy produces significant cardioprotection and markedly prolongs survival in the CM hamster, an idiopathic model of-congestive heart failure.
technical assistance, and we thank Ms. Cari Canon and Ms. Sharon Moffat for their secretarial assistance.
